Bristol Myers Squibb Announces Deucravacitinib Demonstrated Superiority to Placebo and Otezla® in Pivotal Phase 3 Psoriasis Study Biotech Investing
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis Biotech Investing
2nd Annual Gabelli Funds - Columbia Business School Healthcare Symposium - Friday, November 13, 2020 Pharmaceutical Investing
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn Pharmaceutical Investing
Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip Device Medical Device Investing
Algernon Pharmaceuticals Announces Green Light From Data and Safety Monitoring Board to Continue its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 Biotech Investing
Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease Medical Device Investing
Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations Medical Device Investing
AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ in Atopic Dermatitis Biotech Investing
